Boston Scientific (BSX) heads into its next quarterly earnings report with investors weighing softer guidance for 2026 and 2027 against management’s expectation for a product driven recovery starting in 2028.
Recent moves in Boston Scientific reflect that tension between nearer term caution and longer term product hopes. The share price has slipped over the past year, with a 1 year total shareholder return that declined 54.8%, even though the 90 day share price return of 3.3% hints at stabilising momentum ahead of the earnings update as well as ongoing news about slower 2026 to 2027 guidance and expected new launches from 2028.
Spot opportunities beyond Boston Scientific by scanning our hand picked 27 high quality undervalued stocks that combine solid cash generation with balance sheets designed to handle earnings bumps like these.The share price has reset and the gap to both analyst targets and intrinsic value estimates has widened. Where does a reasonable fair value range for Boston Scientific actually sit now?
Most Popular Narrative: 23% Undervalued
Analysts tracking Boston Scientific see a gap between the current share price of $45.69 and their narrative fair value of $59.72. They use a 7.9% discount rate to support that view, which points to a longer recovery path than the market is currently pricing in.
Investment in proprietary, higher margin technologies and acquired platforms is evolving through the planned SEISMIQ coronary IVL launch, the expected completion of the Penumbra acquisition, and the MiRus option on the SIEGEL TAVR valve. Together these initiatives expand Boston Scientific’s exposure to large interventional cardiology and neurovascular markets and are aimed at supporting long term revenue growth and gross margin mix.
See why 86 investors see Boston Scientific as 23% undervalued.
Result: Fair Value of $59.72 (UNDERVALUED)
Still, the narrative breaks if Electrophysiology and WATCHMAN stay weak or if the Penumbra and MiRus deals weigh on Boston Scientific margins for longer than analysts expect.
Find out about the key risks to this Boston Scientific narrative.
Next Steps
Sentiment on Boston Scientific is split. Some are focusing on the weak recent return, while others are focusing on the long term product story. Move quickly, test the numbers yourself, then weigh up the 5 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Boston Scientific?
You do not need to stop with Boston Scientific. Broaden your watchlist now with fresh ideas filtered for quality, resilience, and different risk profiles using objective data.
- Target resilience first by scanning a 30 resilient stocks with low risk scores that focuses on businesses with historically steadier risk profiles than the broader market.
- Hunt for value by reviewing a 21 high quality undiscovered gems that highlights lesser known companies backed by strong underlying fundamentals.
- Prioritise financial strength through a list of solid balance sheet and fundamentals (25 results) that surfaces enterprises built to handle earnings swings and tougher conditions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com